CG Oncology, Inc.: 5%+ holders

As of November 7, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of CG Oncology, Inc. The largest reported stake is RTW Investments, LP's, at 9.7%. 13 filings are on record since August 6, 2025 (Schedule 13G/A, August 14, 2026).

Longitude Capital Partners IV, LLC also filed stake reports on 2 other companies ↓

Sell to companies like CG Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: RTW Investments, LP · Sole voting: 0 · Shared voting: 8,514,590 · Sole dispositive: 0 · Shared dispositive: 8,514,590 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Foresite Capital Fund V, L.P. · Sole voting: 1,079,050 · Shared voting: 0 · Sole dispositive: 1,079,050 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-13 · Reporting person: Wellington Management Group LLP · Sole voting: 0 · Shared voting: 4,637,354 · Sole dispositive: 0 · Shared dispositive: 5,324,751 · SCHEDULE 13G/A, 2026-08-13
• Filing 2026-07-27 · Reporting person: BlackRock, Inc. · Sole voting: 5,914,671 · Shared voting: 0 · Sole dispositive: 6,023,696 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-27
• Filed 2026-05-15 · Holder: RTW Investments, LP · Percent: 8.3% · SCHEDULE 13G

CG Oncology, Inc. has 13 Schedule 13D or 13G filings on record since 2025-08-06. 6 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind CG Oncology, Inc. and the warning signs.

See CG Oncology, Inc.'s free Snapshot Watch CG Oncology, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on CG Oncology, Inc. and the records around it.

CG Oncology, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Longitude Capital Partners IV, LLC also filed stake reports on 2 other companies: Lexeo Therapeutics, Inc. (Nov 2025), ZENAS BIOPHARMA, INC. (Oct 2025)
• Seven Fleet Master Fund LP also filed stake reports on 3 other companies: Entera Bio, Ltd. (the "Issuer") (Aug 2026), CytomX Therapeutics, Inc. (May 2026), Veradermics, Inc (May 2026)
• RTW Investments, LP also filed stake reports on 43 other companies: iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026), ORUKA THERAPEUTICS, INC. (Aug 2026)

Want the whole picture on CG Oncology, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on CG Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on CG Oncology, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   15 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies CG Oncology, Inc. by CUSIP 156944100 and gives its principal executive office as 3000 Pegasus Park Drive, Suite 1640, Dallas, TX 75247 (SCHEDULE 13G/A, 2026-08-14).

Purpose of Transaction (Item 4)

Seven Fleet Partners LP

The Reporting Persons purchased the Shares based on the Reporting Persons' belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in Item 4(a) through (j) of this Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in …The first part of Item 4 of the SCHEDULE 13D filed 2025-09-18; the filing has the rest

Longitude Capital Partners IV, LLC

The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. In addition, Brian Liu, a managing director at LCM, serves on the board of directors of the Issuer. In such capacity, Mr. Liu, as well as other representatives of LCM or the Reporting Entities, expect to engage in communications from time to time with one or more shareholders, officers or members of the …The first part of Item 4 of the SCHEDULE 13D filed 2025-09-18; the filing has the rest

Seven Fleet Capital Management LP

Item 4 of the Schedule 13D is amended to add the following: The Reporting Persons effected an internal restructuring into a master-feeder structure, pursuant to which Seven Fleet Partners LP contributed, for no consideration, all of the 1,515,151 Shares it then held to Seven Fleet Master Fund LP on October 6, 2025 (the "Contribution Date"). Following the Contribution Date, Seven Fleet Partners LP no longer beneficially owns any securities of the Issuer and has ceased to be a reporting person with respect to this Schedule 13D. The restructuring and contribution did not result in any change to Dr. Liu's pecuniary interest in the Shares. This Amendment is being filed pursuant to Rule 13d-2(a) to reflect material changes in the information previously reported, including (i) the restructuring and contribution described above, which changed the identity of the reporting persons and person-level beneficial ownership, and (ii) a correction to the identity of the investment manager disclosed in the initial Schedule 13D. The initial Schedule 13D incorrectly identified "Seven Fleet Advisors" as a reporting person and as the investment manager. The correct investment manager is Seven Fleet Management, and its general partner is Seven Fleet Management GP.Item 4 of the SCHEDULE 13D/A filed 2025-10-28

Timeline

Swipe the table sideways to see every column.

Questions about who owns CG Oncology, Inc.

Who owns CG Oncology, Inc.?

On this page, 6 holders' latest ownership filings report 5% or more of CG Oncology, Inc.: RTW Investments, LP (9.7%, Schedule 13G/A, filed 2026-08-14), T. Rowe Price Investment Management, Inc. (8%, Schedule 13G, filed 2026-05-15), BlackRock, Inc. (6.8%, Schedule 13G/A, filed 2026-07-27), Longitude Capital Partners IV, LLC (6%, Schedule 13D, filed 2025-09-18) and Wellington Management Group LLP (6%, Schedule 13G/A, filed 2026-08-13); 1 more is listed above.

Who are the largest shareholders of CG Oncology, Inc.?

By the share each holder's latest filing reports, the largest holders of CG Oncology, Inc. on this page are RTW Investments, LP (9.7%), T. Rowe Price Investment Management, Inc. (8%) and BlackRock, Inc. (6.8%).

When did RTW Investments, LP buy into CG Oncology, Inc.?

The filings give report dates, not purchase dates. The earliest filing from RTW Investments, LP on this page is the Schedule 13G, filed 2026-05-15, reporting 8.3%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.7%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for CG Oncology, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for CG Oncology, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when CG Oncology, Inc. is mentioned again
• Find former CG Oncology, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes